Biopharma Business

Tag "Alzheimer’s"

Biogen takes up option to co-develop Eisai AD drug

    Biogen takes up option to co-develop Eisai AD drug

Biogen and Eisai have expanded their existing collaboration agreement to develop and commercialise investigational therapies for Alzheimer’s Disease. Eisai has taken up its option to co-develop and co-promote aducanumab, Biogen’s

Read Full Article

Upcoming Events

[eventlist]

The Magazine

New Subscriber

Subscribe Here



Advertisements